SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-16-009534
Filing Date
2016-11-07
Accepted
2016-11-07 16:46:07
Documents
39
Period of Report
2016-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q nvls-20160930x10q.htm 10-Q 999172
2 EX-31.1 nvls-20160930ex311eaa45a.htm EX-31.1 18405
3 EX-31.2 nvls-20160930ex31230070f.htm EX-31.2 18417
4 EX-32.1 nvls-20160930ex3219259ab.htm EX-32.1 8989
  Complete submission text file 0001558370-16-009534.txt   3029235

Data Files

Seq Description Document Type Size
5 EX-101.INS nvls-20160930.xml EX-101.INS 572145
6 EX-101.SCH nvls-20160930.xsd EX-101.SCH 16643
7 EX-101.CAL nvls-20160930_cal.xml EX-101.CAL 25688
8 EX-101.DEF nvls-20160930_def.xml EX-101.DEF 49858
9 EX-101.LAB nvls-20160930_lab.xml EX-101.LAB 184419
10 EX-101.PRE nvls-20160930_pre.xml EX-101.PRE 127231
Mailing Address 3122 STERLING CIRCLE, SUITE 200 BOULDER CO 80301
Business Address 3122 STERLING CIRCLE, SUITE 200 BOULDER CO 80301 720-945-7700
Nivalis Therapeutics, Inc. (Filer) CIK: 0001626199 (see all company filings)

IRS No.: 208969493 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37449 | Film No.: 161978701
SIC: 2834 Pharmaceutical Preparations
Assistant Director 1